Clinical trial
The Open Label Extension Portion of the Study Entitled A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.
NCT00744731 is registered in ClinicalTrials.gov with SK Life Science, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Open Label Extension Portion of the Study Entitled A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.
- Lead sponsor
- SK Life Science, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2009
- Completion date
- August 31, 2010
- Enrollment
- 403 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
epilepsy, complex partial, epilepsy, partial, motor, epilepsy, simple partial, focal motor epilepsy